Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus

Amanat, Fatima; Strohmeier, Shirin; Meade, Philip; Dambrauskas, Nicholas; Mühlemann, Barbara; Smith, Derek J.; Вигдорович, В. И.; Sather, D. Noah; Coughlan, Lynda; Krammer, Florian

doi:10.1371/journal.pbio.3001384

Cited by 16 publications

(12 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previously published SARS-CoV-2 antigenic maps (Amanat et al ., 2021; Lusvarghi et al ., 2022; Mykytyn et al ., 2022; Neerukonda et al ., 2021b; Rössler et al ., 2022; van der Straten et al ., 2022; Wilks et al ., 2022), we found four major variant groups that define the observed limits of SARS-CoV-2 antigenic space ( Fig. 2A ).…”

Section: Resultssupporting

confidence: 92%

“…Techniques that build on antigenic cartography, like antibody landscapes, evaluate how immunological breadth changes following re-exposure versus primary exposure and predict titers against parts of antigenic space that are not yet occupied by variants (Fonville et al, 2014). Very few antigenic maps have been made of SARS-CoV-2, likely because antigenic cartography requires well-characterized sera from individuals with primary exposure to distinct, sequence confirmed variants or experimentally inoculated animals (Amanat et al, 2021; Lusvarghi et al ., 2022; Mykytyn et al, 2022; Neerukonda et al, 2021b; Rössler et al, 2022; van der Straten et al, 2022; Wilks et al, 2022). While the antigenic maps of SARS-CoV-2 published to date agree on the antigenic relationships between the ancestral strain, Delta, Beta, and Omicron, the positions of BA.2, BA.2.12, and BA.4/BA.5 remain uncertain.…”

Section: Introductionmentioning

confidence: 99%

“…Very few antigenic maps have been made of SARS-CoV-2, likely because antigenic cartography requires well-characterized sera from individuals with primary exposure to distinct, sequence confirmed variants or experimentally inoculated animals (Amanat et al, 2021;Lusvarghi et al, 2022;Mykytyn et al, 2022;Neerukonda et al, 2021b;Rössler et al, 2022;van der Straten et al, 2022;Wilks et al, 2022). While the antigenic maps of SARS-CoV-2 published to date agree on and is also made available for use under a CC0 license.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Wang

Lusvarghi

Subramanian

et al. 2022

Preprint

View full text Add to dashboard Cite

SummaryThe rapid emergence of new SARS-CoV-2 variants challenges vaccination strategies. Here, we measured antigenic diversity among variants and interpreted neutralizing antibody responses following single and multiple exposures in longitudinal infection and vaccine cohorts. Antigenic cartography using primary infection antisera showed that BA.2, BA.4/BA.5, and BA.2.12.1 are distinct from BA.1 and closer to the Beta cluster. Three doses of an mRNA COVID-19 vaccine increased breadth to BA.1 more than to BA.4/BA.5 or BA.2.12.1. Omicron BA.1 post-vaccination infection elicited antibody landscapes characterized by broader immunity across antigenic space than three doses alone, although with less breadth than expected to BA.2.12.1 and BA.4/BA.5. Those with Omicron BA.1 infection after two or three vaccinations had similar neutralizing titer magnitude and antigenic breadth. Accounting for antigenic differences among variants of concern when interpreting neutralizing antibody titers aids understanding of complex patterns in humoral immunity and informs selection of future COVID-19 vaccine strains.

show abstract

Section: Resultssupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Wang

Lusvarghi

Subramanian

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…On the other hand, neutralizing titer of Beta and Gamma RBD-Fc (sharing E484K, N501Y, D614G sites) vaccinated groups, was found to be higher against Beta and Gamma strains respectively compared to other immunized groups. Our results are in line with Amanat et al, 48 Based on our results, the SARS-CoV-2 variant-specific vaccine might not cross-react or neutralize all the circulating variants.…”

Section: Discussionsupporting

confidence: 93%

Receptor binding domain proteins of SARS‐CoV‐2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern

Khorattanakulchai

Manopwisedjaroen

Rattanapisit³

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

The constantly emerging severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) variants of concerns (VOCs) with mutations in the receptor-binding domain (RBD) spread rapidly and has become a severe public health problem worldwide.Effective vaccines and optimized booster vaccination strategies are thus highly required. Here, the gene encoding six different RBD (Alpha, Beta, Gamma, Kappa, Delta, and Epsilon variants) along with the Fc fragment of human IgG1 (RBD-Fc) was cloned into plant expression vector and produced in Nicotiana benthamiana by transient expression. Further, the immunogenicity of plant-produced variant RBD-Fc fusion proteins were tested in cynomolgus monkeys. Each group of cynomolgus monkeys was immunized three times intramuscularly with variant RBD-Fc vaccines at Day 0, 21, 42, and neutralizing antibody responses were evaluated against ancestral (Wuhan), Alpha, Beta, Gamma, and Delta variants. The results showed that three doses of the RBD-Fc vaccine significantly enhanced the immune response against all tested SARS-CoV-2 variants. In particular, the vaccines based on Delta and Epsilon mutant RBD elicit broadly neutralizing antibodies against ancestral (Wuhan), Alpha, and Delta SARS-CoV-2 variants whereas Beta and Gamma RBD-Fc vaccines elicit neutralizing antibodies against their respective SARS-CoV-2 strains.The Delta and Epsilon RBD-Fc based vaccines displayed cross-reactive immunogenicity and might be applied as a booster vaccine to induce broadly neutralizing antibodies. These proof-of-concept results will be helpful for the development of plant-derived RBD-Fc-based vaccines against SARS-CoV-2 and its variants.

show abstract

“…BBIBP-CorV has already been licensed for use in China, UAE, and Bahrain and approved for emergency use in many other countries. Sinopharm's vaccine CNBG-WIIBP has been given the green light only for limited use in China and UAE.India also granted approval of Covaxin for emergency use only [8,10,11,12].…”

mentioning

confidence: 99%

Development, Analysis, and Preclinical Evaluation of Inactivated Vaccine Candidate for Prevention of COVID-19 Disease

Onen

Sönmez

Yıldırım

et al. 2022

Preprint

View full text Add to dashboard Cite

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the Chinese capital Wuhan in 2019. Since late 2019, SARS-CoV-2 has been responsible for a global pandemic that has resulted in 405,961,201 confirmed cases of infection and 5,789,567 deaths as of February 11, 2022, according to the World Health Organization (WHO). Here we report the development of an inactivated SARS-CoV-2 vaccine candidate and show that its efficacy and safety in preclinical studies warrant further clinical evaluation. Efficiency and possible side effects of vaccine candidate on different doses were evaluated using histopathology, K18 hACE2 transgenic mice challenge, T-cell response, and serum neutralization test in Balb/c mice. All pilot production and propagation experiments of SARS-CoV-2 were performed in the Level 3 Negative Pressure Biosafety Facility (BSL3/ABSL-3) according to COVID-19 interim guidance of WHO. All analytical studies have shown that the quality control parameters of the vaccine candidate meet the requirements for inactivated viral vaccines according to European Pharmacopeia. Vaccine candidate (KOCAK-19) has been authorized by the Turkish Medicines and Medical Devices Agency and has now entered phase 2 clinical development (NCT04838080).

show abstract

Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus

Cited by 16 publications

References 42 publications

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Receptor binding domain proteins of SARS‐CoV‐2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern

Development, Analysis, and Preclinical Evaluation of Inactivated Vaccine Candidate for Prevention of COVID-19 Disease

Contact Info

Product

Resources

About